Should I use PT-141 as an injection or nasal spray?
PT-141 (bremelanotide) is sold under the FDA-approved brand Vyleesi as a subcutaneous autoinjector for women with low sexual desire, at the dose set by its label and your provider. Compounded versions come as both injections and nasal sprays. Injections tend to have a more predictable onset (about 45 minutes) and a longer effect window (roughly 6-12 hours) but more reported nausea. Nasal sprays tend to kick in faster (20-60 minutes) and wear off faster (up to about 4 hours), which some people prefer for spontaneity. There is no head-to-head trial, so any choice about form and dose is one to make with your provider.
- Vyleesi is the FDA-approved-in-the-US version and is an injection-only product; the specific dose is set by its label and your provider.
- Compounded versions also exist as nasal sprays, an alternative delivery form whose concentration and dosing vary and are decided with your provider.
- Injection onset is roughly 45 minutes with an effect window of about 6-12 hours; nasal onset is faster (20-60 minutes) but wears off sooner (up to about 4 hours).
- Nasal absorption bypasses first-pass metabolism but tends to be more variable person to person.
- Both forms work on the same melanocortin pathway in the brain, so the difference is delivery, not mechanism.
Your guided peptide companion.
PRTCL walks beginners through their first peptide with confidence - guided reconstitution, syringe unit math from your own numbers, vial tracking, and answers to questions like this one. Built for first-timers, useful for everyone.
- · Guided walkthrough for your first dose
- · Your vial and your dose, converted into syringe units
- · Vial inventory and dose log tracking
- · A library where every claim cites its source
Free to start.